MR‐proADM as a Prognostic Marker in Patients With ST‐Segment–Elevation Myocardial Infarction—DANAMI‐3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy

MR‐proADM as a Prognostic Marker in Patients With ST‐Segment–Elevation Myocardial Infarction—DANAMI‐3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy

BackgroundMidregional proadrenomedullin (MR‐proADM) has demonstrated prognostic potential after myocardial infarction (MI). Yet, the prognostic value of MR‐proADM at admission has not been examined in patients with ST‐segment–elevation MI (STEMI). Methods and ResultsThe aim of this substudy, DANAMI‐...

Full description

Bibliographic Details
Main Authors: Alexander C. Falkentoft, Rasmus Rørth, Kasper Iversen, Dan E. Høfsten, Henning Kelbæk, Lene Holmvang, Martin Frydland, Mikkel M. Schoos, Steffen Helqvist, Anna Axelsson, Peter Clemmensen, Erik Jørgensen, Kari Saunamäki, Hans‐Henrik Tilsted, Frants Pedersen, Christian Torp‐Pedersen, Klaus F. Kofoed, Jens P. Goetze, Thomas Engstrøm, Lars Køber
Format: Article
Language:English
Published: Wiley 2018-06-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
biomarker
midregional proadrenomedullin
myocardial infarction
prognosis
ST‐segment–elevation myocardial infarction
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.117.008123

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.117.008123

Similar Items